Hepion Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-8.28	-13.19	-48.93	-42.2	-32.72	Upgrade
Depreciation & Amortization	-	0.03	0.07	0.08	0.09	Upgrade
Other Amortization	-	1.27	-	-	-	Upgrade
Asset Writedown & Restructuring Costs	0.4	-	3.19	1.87	-	Upgrade
Stock-Based Compensation	0.02	0.79	1.34	2.55	4.67	Upgrade
Other Operating Activities	4.09	-4.43	0.47	-0.41	2.31	Upgrade
Change in Accounts Payable	0	-4.55	0.3	2.25	-1.07	Upgrade
Change in Other Net Operating Assets	0.49	1.86	2.67	0.91	-4.5	Upgrade
Operating Cash Flow	-3.27	-18.22	-40.89	-34.96	-31.22	Upgrade
Capital Expenditures	-	-	-0.01	-0.02	-0.13	Upgrade
Sale of Property, Plant & Equipment	-	-	-	0	-	Upgrade
Sale (Purchase) of Intangibles	-0.13	-	-	-	-	Upgrade
Other Investing Activities	-	-0.6	-	-	-	Upgrade
Investing Cash Flow	-0.13	-0.6	-0.01	-0.01	-0.13	Upgrade
Short-Term Debt Repaid	-3.37	-	-	-	-	Upgrade
Long-Term Debt Repaid	-	-	-	-	-0.18	Upgrade
Total Debt Repaid	-3.37	-	-	-	-0.18	Upgrade
Net Debt Issued (Repaid)	-3.37	-	-	-	-0.18	Upgrade
Issuance of Common Stock	9	4.35	4.49	-	82.15	Upgrade
Other Financing Activities	-0.8	-	-	-2	-	Upgrade
Financing Cash Flow	4.83	4.35	4.49	-5.14	81.98	Upgrade
Foreign Exchange Rate Adjustments	-	0.09	0.01	-0.05	-	Upgrade
Net Cash Flow	1.42	-14.38	-36.4	-40.16	50.62	Upgrade
Free Cash Flow	-3.27	-18.22	-40.9	-34.98	-31.35	Upgrade
Free Cash Flow Per Share	-0.35	-148.23	-515.05	-458.85	-446.07	Upgrade
Cash Interest Paid	0.02	-	-	0	0	Upgrade
Levered Free Cash Flow	-2.51	-14.22	-25.88	-23.97	-15.02	Upgrade
Unlevered Free Cash Flow	-2.5	-14.7	-25.87	-23.96	-15.02	Upgrade
Change in Working Capital	0.49	-2.68	2.97	3.15	-5.57	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.